Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056760
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Viatris collaboration agreement | $17,699 | $15,388 |
| Total revenues | 17,699 | 15,388 |
| Expenses: | ||
| Research and development (1) | 5,829 | 11,452 |
| Selling, general and administrative (1) | 17,720 | 18,370 |
| Restructuring expenses (1) (2) | 3,633 | — |
| Total expenses | 27,182 | 29,822 |
| Loss from operations | (9,483) | (14,434) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's R&D?
- Theravance Biopharma (TBPH) reported R&D of $5.83M in Q1 2026.
- How has Theravance Biopharma's R&D changed year-over-year?
- Theravance Biopharma's R&D decreased by 49.1% year-over-year, from $11.45M to $5.83M.
- What is the long-term trend for Theravance Biopharma's R&D?
- Over 4 years (2021 to 2025), Theravance Biopharma's R&D has grown at a -33.7% compound annual growth rate (CAGR), from $193.66M to $37.41M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Theravance Biopharma's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude